3-(苯并[d][1,3]二氧代-5-基)-1-丙胺 | 78498-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 3-(苯并[d][1,3]二氧代-5-基)-1-丙胺
• 英文名称: 3-<-3,4-(methylenedioxy)phenyl>-1-aminopropane
• 英文别名: 1,3-Benzodioxole-5-propanamine；3-(1,3-benzodioxol-5-yl)propan-1-amine
• CAS: 78498-59-6
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD07374100
• 分子量: 179.219
• InChiKey: CLJLCLGOWKOKJF-UHFFFAOYSA-N

物化性质

• 沸点：
  145 °C(Press: 16 Torr)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(苯并[d][1,3]二氧代-5-基)-1-丙胺 在 硼烷四氢呋喃络合物 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲苯 、 乙腈 为溶剂， 反应 86.0h， 生成 1-[(3,4,5-trimethoxyphenyl)methyl]-7,8-(methylenedioxy)-2,3,4,5-tetrhydro-1H-2-benzazepine
  参考文献：
  名称：

  Synthesis and investigation of the .alpha.-adrenoceptor agonist and platelet antiaggregatory properties of 1,7,8-trisubstituted 2,3,4,5-tetrahydro-1H-2-benzazepine analogs of trimetoquinol

  摘要：

  The synthesis and biological evaluation of 7,8-dihydroxy (2) and 7,8-methylenedioxy (3) analogues of 1-[(3,4,5-trimethyoxyphenyl)methyl]-2,3,4,5-tetradhyo-1H-2-b enzazepine on beta-adrenoceptor systems and human platelets were undertaken and compared with trimetoquinol (TMQ, 1). Whereas 1 is a potent beta-adrenoceptor agonist in guinea pig atria and trachea (pD2 = 8.2), analogue 2 was marginally effective at relaxing guinea pig tracheal smooth muscle (pD2 = 4.4) and inactive as an agonist on guinea pig atria. Analogues 2 and 3 were inhibitors of phospholipase C (PLC; from Clostridium perfringens) induced and secondary wave of ADP-induced aggregation responses and inactive against low-dose thrombin-induced or stable endoperoxide (U46619) induced human platelet aggregation. Against ADP-induced serotonin secretion, 3 was 9-fold more active than analogue 2. Further, the rank order of TMQ isomers and 3 as inhibitors of PLC-induced platelet aggregation, serotonin secretion, and phosphatidylinositol degradation was identical (3 greater than (S)-(-)-1 greater than (R)-(+)-1). The results suggest that these compounds are blocking the action of PLC by interfering with phosphatidylinositol turnover in platelet membranes. The inhibition of ADP-induced responses in human platelets by analogues 2 and 3 also suggests a site of inhibition at a level of arachidonic acid release. Thus, ring expansion of 1 as in the benzazepine analogues 2 and 3 has allowed us to develop selective inhibitors of platelet function that lack significant beta-adrenoceptor activity.

  DOI：

  10.1021/jm00152a003
• 作为产物：
  描述：

  黄樟素 在 (S)-(+)-5,5'-双[二(3,5-二叔丁基-4-甲氧基苯基)膦]-4,4'-二-1,3-苯并二氧戊环 、 氨 、 copper diacetate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 15.33h， 生成 3-(苯并[d][1,3]二氧代-5-基)-1-丙胺
  参考文献：
  名称：

  铜催化加氢胺化合成手性伯胺的实用亲电氮源

  摘要：

  在烯烃和炔烃之间催化安装氨基的温和实用方法长期以来一直被认为是合成化学中的重大挑战。由于使用氨直接对烯烃加氢胺化需要苛刻的条件，因此为正式加氢胺化方法开发合适的亲电胺化试剂具有重要意义。在此，我们描述了使用 1,2-苯并异恶唑作为实用的亲电伯胺源。使用这种杂环作为新的氨基传递剂，开发了一种温和的通用方案，用于氢化铜催化烯烃和炔烃的加氢胺化以形成伯胺。该方法提供了获得广泛的手性 α-支化伯胺和线性伯胺的途径，

  DOI：

  10.1021/jacs.8b10564

文献信息

• Inducible nitric oxide synthase dimerization inhibitors
  申请人：Gahman C. Timothy

  公开号：US20060116515A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR 4 , N, NR 4 , S, and O; U is selected from the group consisting of CR 10 and N; V is selected from the group consisting of CR 4 and N; W and W′ are independently selected from the group consisting of CH 2 , CR 7 R 8 , NR 9 , O, N(O), S(O) q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

  本发明涉及化合物和方法，用作一氧化氮合酶的抑制剂。本发明的某些化合物具有以下结构式： 其中T、X和Y分别选自CR 4 、N、NR 4 、S和O组成的群；U选自CR 10 和N组成的群；V选自CR 4 和N组成的群；W和W′分别选自CH 2 、CR 7 R 8 、NR 9 、O、N(O)、S(O) q 和C(O)组成的群；n、m和p分别是从0到5的整数；q为0、1或2；其他取代基如本文所定义。本发明的其他化合物具有如本文所定义的结构式。本文还公开了包含本发明化合物的药物组合物。
• Structure-Activity Relationships of 6-Nitroquinazolines: Dual-Acting Compounds with Inhibitory Activities toward both TNF-.ALPHA. Production and T Cell Proliferation.
  作者：Masanori Tobe、Yoshiaki Isobe、Hideyuki Tomizawa、Takahiro Nagasaki、Fumihiro Obara、Mitsuhiro Matsumoto、Hideya Hayashi

  DOI：10.1248/cpb.50.1073

  日期：——

  We synthesized various 6-nitroquinazolines by modifying the structure of compound 1 and evaluated their inhibitory activities toward both TNF-α production and T cell proliferation responses. The presence of the unsubstituted piperazine ring at the C(7)-position was required for both inhibitory activities. In this series of compounds, 5d and 5f, containing the 4-fluorophenyl and 3,4-difluorophenyl moiety, respectively, at the C(4)-position, showed the suppressing effects toward both responses with low cell growth inhibition. Furthermore, the oral administration of these compounds mentioned above at doses of 30 and 100 mg/kg also resulted in significant inhibition of TNF-α production induced by LPS in vivo.

  我们通过修改化合物1的结构合成了多种6-硝基喹唑啉，并评估了它们对TNF-α产生和T细胞增殖反应的抑制活性。在C(7)位上，需要存在未取代的哌嗪环才能发挥这两种抑制活性。在这一系列化合物中，5d和5f分别在C(4)位包含了4-氟苯基和3,4-二氟苯基，它们对这两种反应显示出抑制效果，同时对细胞生长的抑制较低。此外，口服给予上述化合物的剂量为30和100 mg/kg时，在体内也显著抑制了LPS诱导的TNF-α产生。
• Phenylacetamide derivatives and pharmaceutical compositions thereof
  申请人：Korea Research Institute of Chemical Technology

  公开号：US05242944A1

  公开（公告）日：1993-09-07

  The present invention provides novel phenylacetamide derivatives having the following formula ##STR1## wherein: X is a hydrogen, halogen, hydroxy, nitro, amino, R.sup.1, NR.sup.1 R.sup.2, NHR.sup.1 or OR.sup.1 wherein R.sup.1 and R.sup.2 are an optionally substituted C.sub.1-8 alkyl, cycloalkyl or benzyl group, respectively; Y, which may be the same or different when p is greater than 1, is a hydrogen, halogen, methylenedioxy, hydroxy, trifluoromethyl, R.sup.3 or OR.sup.3 wherein R.sup.3 is an optionally substituted C.sub.1-8 alkyl or benzyl group; n is an integer from 1 to 6; and p is an integer from 1 to 5; and pharmaceutically acceptable salts thereof which have powerful analgesic and anti-inflammatory activities. The invention also provides processes for preparing these compounds and pharmaceutical compositions containing them as an active ingredient.

  本发明提供了具有以下结构的新型苯乙酰胺衍生物 ##STR1## 其中：X为氢、卤素、羟基、硝基、氨基、R.sup.1、NR.sup.1 R.sup.2、NHR.sup.1或OR.sup.1，其中R.sup.1和R.sup.2分别为可选择取代的C.sub.1-8烷基、环烷基或苄基；Y，当p大于1时可能相同或不同，为氢、卤素、亚甲二氧基、羟基、三氟甲基、R.sup.3或OR.sup.3，其中R.sup.3为可选择取代的C.sub.1-8烷基或苄基；n为1至6的整数；p为1至5的整数；以及具有强力镇痛和抗炎活性的药用盐。本发明还提供了制备这些化合物的方法和含有它们作为活性成分的药物组合物。
• Synthesis of erythrina and related alkaloids. XXII. Intramolecular cyclization approach. 1): New synthetic route to erythrinan and related heterocycles and synthesis of (.+-.)-3-demethoxy-erythratidinone.
  作者：Yoshisuke TSUDA、Yuki SAKAI、Akira NAKAI、Mari KANEKO、Yukie ISHIGURO、Kimiaki ISOBE、Jun-ichi TAGA、Takehiro SANO

  DOI：10.1248/cpb.38.1462

  日期：——

  Heating of cycloalkanone-2-carboxylate with β-arylethylamine, and oxalylation of the resulting enamino-ester followed by Lewis acid-catalyzed intramolecular cyclization afforded various erythrinan-type heterocycles in excellent yields. This method is widely applicable not only to the synthesis of erythrinans but also to that of A-nor and A-homo analogs and ring-D variants of erythrinan. The alkoxycarbonyl group on the products was readily removed by a new decarbalkoxylation method (heating with magnesium chloride-dimethyl sulfoxide combination). Thus, starting from 2-ethoxycarbonyl-4, 4-ethylenedioxy-cyclohexanone, the 2, 8-dioxo-erythrinan derivative (35) was synthesized in several steps in high yield, and was readily converted to the natural Erythrina alkaloid, 3-demethoxyerythratidinone.

  将环烷酮-2-羧酸酯与β-芳基乙胺加热，并对所得到的烯胺酯进行草酰化，随后经过路易斯酸催化的分子内环化反应，可以很好地获得多种红豆杉类杂环化合物。该方法不仅广泛适用于红豆杉类化合物的合成，还可用于A-去甲基和A-同源物以及红豆杉的环-D变体的合成。产品中的烷氧羰基团可以通过一种新的去羧基化方法（与氯化镁-二甲基亚硫酰胺的组合加热）轻松去除。因此，从2-乙氧羰基-4,4-乙烯基二氧环己酮出发，经过几步反应以高产率合成了2,8-二氧红豆杉派生物（35），并可以很容易地转化为天然红豆杉生物碱3-去甲氧基红豆杉啶酮。
• Developing Amphetamine Certified Reference Materials: From Batch and Continuous‐Flow Synthesis to Certification Protocol
  作者：Thais G. Silva、Rodrigo O. M. A. de Souza、Bruno C. Garrido、Eliane C. P. do Rego、Wagner Wollinger、Fernanda G. Finelli

  DOI：10.1002/cplu.202300384

  日期：2023.10

  Development of a comprehensive protocol for the production of Certified Reference Materials (CRM) of amphetamine and related compounds from a simple, rapid, and efficient synthesis under batch and continuous-flow conditions are reported in this work, accompanied by the establishment of a certification procedure for these materials through identity checking, homogeneity, stability, and characterization

  这项工作报告了在批量和连续流动条件下通过简单、快速、高效的合成生产安非他明和相关化合物的有证标准物质 (CRM) 的综合方案的开发，并建立了认证程序通过身份检查、同质性、稳定性和表征研究对这些材料进行研究。